The 2023 Fellowships are financially supported through the Forward Fund, which was established by SITC to stimulate the future of science, development and application of cancer immunology and immunotherapy through financially supporting its education and research. Since 2014, SITC has awarded more than $6 million in funding to deserving early career scientists in the field of cancer immunotherapy.
The 2023 SITC Fellowship recipients are:
SITC-Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship
Award Amount: $200,000 (two-year)
Awardee: Tyler E. Miller, MD, PhD
Institution: Massachusetts General Hospital
Project Title: “Identifying interventions that target the immunosuppressive microenvironment in solid tumors”
SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship
Award Amount: $100,000 (one-year)
Awardee: Pamela Basto, MD, PhD
Institution: Stanford University
Project Title: “Development of Cellular Therapies Targeting Aberrant Glycosylation in Lung Adenocarcinoma”
SITC-Genentech Women in Cancer Immunotherapy Fellowship
Award Amount: $100,000 (one-year)
Awardee: Kylynda C. Bauer, PhD
Institution: National Cancer Institute
Project Title: “Vagal-CD8+ T cell axis: Harnessing neuroimmune circuits to alter anti-tumor immunity in liver cancer”
SITC-Merck Cancer Immunotherapy Clinical Fellowship
Award Amount: $100,000 (one-year)
Awardee: Eisuke Tomiyama, MD, PhD
Institution: University of British Columbia
Project Title: “Elucidation of the role of EphA2 in the immune evasion of bladder cancer to overcome resistance to immune-checkpoint inhibitors”
SITC Diversity, Equity and Inclusion Fellowship
Award Amount: $100,000 (one-year)
Awardee: Shaquia L. Idlett-Ali, PhD
Institution: University of Colorado
Project Title: “Targeting nerve-mediated immunosuppression in the tumor microenvironment for head and neck squamous cell carcinoma”
SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship
Award Amount: $40,000 (one-year)
Awardee: Guido Ghilardi, MD
Institution: University of Pennsylvania
Project Title: “The role of lymphodepletion in CAR T cell-associated toxicities”
This year’s SITC Forward Fund Fellowships were made possible through the generosity of AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, Mallinckrodt Pharmaceuticals and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
The fellowship recipients will be honored during a ceremony at the society’s 38th Annual Meeting, at the San Diego Convention Center in San Diego, CA.
To learn more about current and past SITC Fellowship recipients, visit SITC’s website.
About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook, Instagram and YouTube.
Media Contact
Thomas Martin, Society for Immunotherapy of Cancer, 414-271-2456, [email protected], sitcancer.org
SOURCE Society for Immunotherapy of Cancer
